PET to Measure Breast Cancer Bone Metastasis Response

PET 测量乳腺癌骨转移反应

基本信息

批准号：
8092558
负责人：
Jennifer Marie Specht
金额：
$ 36.25万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-01 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8092558
关键词：
Appearance Behavior Biologic Characteristic Biology Biopsy Bone Regeneration Bone neoplasms Bone remodeling Cancer Patient Characteristics Clinical Clinical Trials Early treatment Energy Metabolism Equilibrium Event Exhibits Flare Fluorides Fracture Goals Gold Healed Hormone Receptor Image Investigation Kinetics Lesion Lytic Lytic Lesion Mammary Neoplasms Measures Metabolism Metastatic Neoplasm to the Bone Nature Neoplasm Metastasis Osteolytic Outcome Outcome Measure PET/CT scan Patients Physiologic calcification Positron-Emission Tomography Primary Neoplasm Property Prospective Studies Proteins Reaction Time Relative (related person)Research Personnel Retrospective Studies Risk Serum Site Systemic Therapy Testing Time Tumor necrosis factor receptor 11b Urine Visceral X-Ray Computed Tomography base bisphosphonate bone bone healing bone imaging bone turnover chemotherapy clinical practice effective therapy fluorodeoxyglucose positron emission tomography healing hormone therapy imaging modality in vitro Assay in vivo indexing malignant breast neoplasm outcome forecast prevent programs response skeletal tumor uptake

项目摘要

DESCRIPTION (provided by applicant): Bone is a common site of metastasis for breast cancer. Although rarely "cured" of breast cancer, patients with bone-dominant breast cancer have a more favorable prognosis than patients with visceral involvement and may have prolonged survival. These patients benefit from an increasing array of effective therapies; however, the choice of therapy is hampered by the difficulty of assessing response. We have shown, in retrospective studies, that serial FDG PET can measure bone metastasis response to therapy, that changes in FDG uptake with treatment predict time-to-progression (TTP), and that the level of FDG uptake predicts the likelihood of skeletal-related events (SRE), such as fracture. We have also used 18F-fluoride PET to assess tumor effect on the1 bone adjacent to metastases and have shown that the information gained on bone metastasis behavior from fluoride PET is distinct from and complementary to FDG PET. We now propose to extend these preliminary studies to a larger prospective study of FDG and fluoride PET in patients with bone-dominant breast cancer undergoing systemic therapy. Our aims are (1) to prospectively validate FDG and fluoride PET as measures of bone metastasis response to therapy with patient outcome as the gold standard, (2) to measure the in vivo biology of metastatic sites and adjacent bone using a combination of quantitative FDG PET/CT and fluoride PET with the goal of predicting the risk of a skeletal event and also to relate PET measures to tumor characteristics measured by in vitro assay of biopsy material, and (3) to measure the early effect of bisphosphonates on bone turnover using fluoride PET to better understand the in vivo effect of these agents, which are almost universally used in treating breast cancer metastases. The result of these investigations will be imaging methods, validated by patient outcome, for measuring breast cancer bone metastasis response in clinical trials and clinical practice and for directing appropriate early interventions to prevent skeletal events.

描述（由申请人提供）：骨骼是乳腺癌转移的常见部位。尽管很少对乳腺癌“治愈”，但骨出现的乳腺癌患者的预后比内脏受累的患者更有利，并且可能长期生存。这些患者受益于越来越多的有效疗法。但是，评估反应的困难会阻碍治疗的选择。在回顾性研究中，我们已经表明，连续的FDG PET可以测量骨转移对治疗的反应，即通过治疗预测产生时间的FDG摄取的变化（TTP），而FDG摄取水平可以预测骨架 - 骨架的可能性。相关事件（SRE），例如断裂。我们还使用了18F氟化物PET来评估肿瘤对转移相邻的骨骼的影响，并表明，氟化物PET的骨转移行为获得的信息与FDG PET不同，与FDG PET相互互补。现在，我们建议将这些初步研究扩展到在接受全身治疗的骨骼主导乳腺癌患者中对FDG和氟化物PET进行更大的前瞻性研究。我们的目的是（1）前瞻性地验证FDG和氟化物PET作为骨转移对患者预后治疗的骨转移反应的测量，（2），（2）使用定量FDG的组合来测量转移性位点的体内生物学和相邻骨骼的体内生物学PET/CT和氟化物PET的目的是预测骨骼事件的风险，并将PET措施与通过活检材料的体外测定测量所测量的肿瘤特征，以及（3）测量双膦酸盐对使用骨转换对骨转换的早期影响氟化物宠物可以更好地了解这些药物的体内效应，这些效果几乎普遍用于治疗乳腺癌转移。这些研究的结果将是通过患者结局验证的成像方法，用于在临床试验和临床实践中测量乳腺癌骨转移反应，并指导适当的早期干预措施以防止骨骼事件。